From Nobel Discovery to Clinical Application: Mirxes Is Transforming Cancer Early Screening with miRNA Technology | Gaorong Ventures
Focused on miRNA technology development, pioneering early cancer screening worldwide.
高榕创投
@gaorong
创造美好生活
522 articles
Articles
When a "Top-Tier" Gene-Editing Scientist Team Starts Caring About Seeds, Grains, and Vegetables | Gaorong Ventures
Let harvests be not only nature's gift, but also the fruit of technology.
Celebrating the splendor of our land, building dreams for every home. Gaorong Ventures wishes you a joyful National Day!
Gaorong Ventures wishes you a happy National Day holiday!
Li Xilie: Former Head of Bayer and Medtronic Asia-Pacific on Nine Strategies for Chinese Healthcare Companies Going Global | Ronghui Practical Insights
"Nine Questions" for Chinese Healthcare Companies Going Global
Outlook on Hong Kong IPO Opportunities: Uncovering Three Advantages — "Profit Improvement, Globalization, and Sector Leadership" | Ronghui
Embrace innovative mechanisms and leverage corporate strengths.
Gazing up at the bright moon and the river of stars, we paint the future of innovation. Gaorong Ventures wishes you a happy Mid-Autumn Festival!
Gaorong Ventures wishes you a happy Mid-Autumn Festival!
Rongbao | Embodied intelligence, chips accelerate commercial rollout and R&D; AI transforms creative industries, finance, and more
Several companies made it onto the annual lists by *China Entrepreneur* and *Fortune*.
At the Intersection of Generative AI and Life Sciences: Technology Acceleration on One Side, Clinical Demand on the Other | Ronghui x NVIDIA Inception Program
NVIDIA, Gaorong Ventures, and Cornerstone Robotics on the Acceleration of "AI + Healthcare"
AI Product Growth: Before Talking PMF, First Achieve AI Market Fit | Ronghui Practical Insights
The defining feature of future AI-native products will be that the product adapts to the person, not the other way around.
AIRNA Closes $90 Million Series A to Advance Novel RNA-Editing Therapeutics
Accelerate the advancement of best-in-class drug candidates into clinical trials.